Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload
Lin Shi, Diqi Zhu, Shoubao Wang, et al.
American Journal of Hypertension (2019) Vol. 32, Iss. 5, pp. 452-459
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Gary D. Lopaschuk, Subodh Verma
JACC Basic to Translational Science (2020) Vol. 5, Iss. 6, pp. 632-644
Open Access | Times Cited: 614
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches
Begoña López, Susana Ravassa, María U. Moreno, et al.
Nature Reviews Cardiology (2021) Vol. 18, Iss. 7, pp. 479-498
Closed Access | Times Cited: 222
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
Coenraad Withaar, Laura M G Meems, George Markousis‐Mavrogenis, et al.
Cardiovascular Research (2020) Vol. 117, Iss. 9, pp. 2108-2124
Open Access | Times Cited: 157
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Shruti Joshi, Trisha Singh, David E. Newby, et al.
Heart (2021) Vol. 107, Iss. 13, pp. 1032-1038
Open Access | Times Cited: 137
The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Yuliya Lytvyn, Petter Bjornstad, Daniël H. van Raalte, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 2, pp. 202-231
Open Access | Times Cited: 113
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, et al.
Current Heart Failure Reports (2021) Vol. 18, Iss. 5, pp. 315-328
Open Access | Times Cited: 76
SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
Ioanna Andreadou, Robert M. Bell, Hans Erik Bøtker, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2020) Vol. 1866, Iss. 7, pp. 165770-165770
Open Access | Times Cited: 73
Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis
Nan Zhang, Yueying Wang, Gary Tse, et al.
European Journal of Preventive Cardiology (2021) Vol. 28, Iss. 17, pp. 1961-1973
Closed Access | Times Cited: 61
Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials
Dimitrios Sfairopoulos, Nan Zhang, Yueying Wang, et al.
EP Europace (2021) Vol. 24, Iss. 1, pp. 20-30
Open Access | Times Cited: 59
Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress
Fangfang Ren, Zuo-yi Xie, Yina Jiang, et al.
Acta Pharmacologica Sinica (2021) Vol. 43, Iss. 7, pp. 1721-1732
Open Access | Times Cited: 56
Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients – DACAMI (a randomized controlled clinical trial)
Khairy Abdel Dayem, Omar Younis, Bassem Zarif, et al.
International Journal of Cardiology (2023) Vol. 379, pp. 9-14
Closed Access | Times Cited: 27
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
B K Chen, Jing Guo, Ye Hongmei, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 5
Open Access | Times Cited: 9
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Subodh Verma
The American Journal of Cardiology (2019) Vol. 124, pp. S36-S44
Open Access | Times Cited: 74
Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
Maximilian Trum, Johannes Riechel, Stefan Wagner
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 7976-7976
Open Access | Times Cited: 54
Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review
Cristina Panico, Benedetta Maria Bonora, Antonella Camera, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland
Anastasios Lymperopoulos, Jordana I. Borges, Natalie Cora, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7684-7684
Open Access | Times Cited: 40
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
Riccardo Nevola, Maria Rosaria Alfano, Pia Clara Pafundi, et al.
Reviews in Cardiovascular Medicine (2022) Vol. 23, Iss. 3
Open Access | Times Cited: 25
Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins
Raúl Sanz, Felipe Inserra, Sebastián García Menéndez, et al.
Current Hypertension Reports (2023) Vol. 25, Iss. 6, pp. 91-106
Closed Access | Times Cited: 13
Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice
Elaf Mahmood Shihab, Haitham Mahmood Kadhim, Samer Salim Shahooth
Journal of Medicine and Life (2024) Vol. 17, Iss. 2, pp. 157-163
Open Access | Times Cited: 5
Benefits of SGLT2 inhibitors in arrhythmias
Jinghan Gao, Genlong Xue, Ge Zhan, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 20
New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
Yang Chen, Daoquan Peng
International Immunopharmacology (2023) Vol. 118, pp. 110072-110072
Open Access | Times Cited: 12
Prescribing patterns of SGLT-2 inhibitors and their association with heart failure readmissions: a single-center cross-sectional study from a low- and middle-income country
Abrar Ali Chhachhar, Saadia Sattar, Farhala Baloch, et al.
Hospital Practice (2025) Vol. 53, Iss. 1
Closed Access
Effects of SGLT2 inhibitors on health-related quality of life and functional capacity in patients with heart failure with and without diabetes: a meta-analysis of randomized controlled trials
Mariana de Moura de Souza, Maria Luiza Rodrigues Defante, Bianca Costa de Morais, et al.
International Journal of Clinical Pharmacy (2025)
Closed Access
The role and molecular mechanism of FoxO1 in mediating cardiac hypertrophy
Wei Yu, Chunjuan Chen, Jidong Cheng
ESC Heart Failure (2020) Vol. 7, Iss. 6, pp. 3497-3504
Open Access | Times Cited: 32
Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
Yoshiaki Kubota, Wataru Shimizu
JACC Asia (2022) Vol. 2, Iss. 3, pp. 287-293
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top